These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 645405)

  • 1. The purely neuroleptic effects and its relation to the "neuroleptic threshold".
    Haase HJ
    Acta Psychiatr Belg; 1978; 78(1):19-36. PubMed ID: 645405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of schizophrenic psychoses using low-potency neuroleptics].
    Kemperdick KT; Nieling C; Steinig A
    Med Klin; 1967 Sep; 62(39):1512-5. PubMed ID: 5596490
    [No Abstract]   [Full Text] [Related]  

  • 3. [Oral glucose tolerance test in schizophrenics under long-term neuroleptic treatment (author's transl)].
    Gonçalves N; Grüneberg F
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Sep; 8(5):289-95. PubMed ID: 1233523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia].
    Elie R; Gagnon MA; Gauthier R; Jéquier JC
    Union Med Can; 1975 Jun; 104(6):909-14. PubMed ID: 772906
    [No Abstract]   [Full Text] [Related]  

  • 5. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Time relationship between the appearance of persisting extrapyramidal hyperkineses and psychotic recurrences following sudden interruption of prolonged neuroleptic therapy of chronic schizophrenic patients].
    Degkwitz R; Bauer MP; Gruber M; Hampel G; Luxenburger O; Richartz M; Wenzel W
    Arzneimittelforschung; 1970 Jul; 20(7):890-3. PubMed ID: 4918918
    [No Abstract]   [Full Text] [Related]  

  • 8. [Psychometric effects of perphenacine below the "neuroleptic threshold" (author's transl)].
    Jacobi P; Maxion HH
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Dec; 8(6):366-74. PubMed ID: 1233531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Handwriting changes and response to drugs--a controlled study.
    Angus JW; Simpson GM
    Acta Psychiatr Scand Suppl; 1970; 212():28-37. PubMed ID: 4917969
    [No Abstract]   [Full Text] [Related]  

  • 10. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
    Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M
    Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112
    [No Abstract]   [Full Text] [Related]  

  • 11. [Present-day possibilities of relieving post-neuroleptic extrapyramidal symptoms].
    Wasik A
    Psychiatr Pol; 1973; 7(1):51-6. PubMed ID: 4715833
    [No Abstract]   [Full Text] [Related]  

  • 12. An attempt to classify neuroleptic drugs on the basis of short-term clinical comparative studies.
    Rodová A; Náhunek K; Svestka J
    Act Nerv Super (Praha); 1974 Aug; 16(3):169-70. PubMed ID: 4609274
    [No Abstract]   [Full Text] [Related]  

  • 13. The extrapyramidal neuroleptic syndrome: description and measurement.
    Elie R; Gagnon MA; Lamontagne Y; Tetreault L
    Curr Ther Res Clin Exp; 1973 Jul; 15(7):427-40. PubMed ID: 4198304
    [No Abstract]   [Full Text] [Related]  

  • 14. [Late irreversible extrapyramidal syndrome following neuroleptic use].
    Boucebci M
    Acta Psychiatr Belg; 1972 Mar; 72(2):233-40. PubMed ID: 5056017
    [No Abstract]   [Full Text] [Related]  

  • 15. Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs.
    HAASE HJ
    Rev Can Biol; 1961 Jun; 20():425-49. PubMed ID: 13903363
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of octoclothepine on sensorimotor coordination of fine movements in chronic schizophrenics.
    Remr J
    Act Nerv Super (Praha); 1972; 14(2):90-1. PubMed ID: 5040177
    [No Abstract]   [Full Text] [Related]  

  • 17. [Usefulness for differential diagnosis of the distribution of extrapyramidal symptoms resulting from neuroleptic therapy in psychiatric practice].
    Bódog G
    Psychiatr Neurol Med Psychol (Leipz); 1976 Jan; 28(1):51-7. PubMed ID: 940883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The handwriting test as an aid to neuroleptic dosage.
    Küstner U; Müller-Oerlinghausen B
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S34-41. PubMed ID: 2878893
    [No Abstract]   [Full Text] [Related]  

  • 19. A preliminary study of Thiothixene in chronic schizophrenics.
    Simpson GM; Iqbal J
    Curr Ther Res Clin Exp; 1965 Nov; 7(11):697-700. PubMed ID: 4953690
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.